FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2005 Meditech Pharmaceuticals Inc. --------------------------------------- (Exact name of registrant as specified in its charter) Nevada 000-12561 95-3819300 - ------------------------ --------------------- ------------------- (State of Incorporation) (Commission File No.) (IRS Employer Identification No.) 558 Lime Rock Road, Lime Rock, Connecticut 06039 (Address of principal execute offices, including zip code) (860)435-7000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ITEM 9.01 Financial Statements and Exhibits --------------------------------- (c) Exhibits Name of Exhibit --------- --------------- 99.1 Press release of Registrant dated April 7, 2005. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 7, 2005 Meditech Pharmaceuticals, Inc. (Registrant) By: /s/ Deli Du ------------------------------------- Deli Du President and Chief Executive Officer
- CSOL Dashboard
- Filings
-
8-K Filing
China Solar & Clean Energy Solutions (CSOL) 8-KFinancial Statements and Exhibits
Filed: 7 Apr 05, 12:00am